Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study).

[1]  M. Matsuhisa,et al.  Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study) , 2020, Expert opinion on pharmacotherapy.

[2]  A. Goto,et al.  Japanese Clinical Practice Guideline for Diabetes 2019 , 2020, Diabetology International.

[3]  H. Maegawa,et al.  A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes , 2020, Diabetes Therapy.

[4]  H. Kaneto,et al.  Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge , 2020, Diabetes, obesity & metabolism.

[5]  J. Rosenstock,et al.  Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial , 2020, Diabetes, obesity & metabolism.

[6]  ofMedicalCare inDiabetesd,et al.  7. Diabetes Technology: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[7]  M. Odawara,et al.  Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database , 2019, Diabetology & Metabolic Syndrome.

[8]  A. Sinclair,et al.  Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. , 2020, Diabetes & metabolism.

[9]  I. Idris,et al.  The Trend of High-Dose Insulin Usage Among Patients with Diabetes in the UK: A Retrospective Study , 2018, Diabetes Therapy.

[10]  A. Merino-Trigo,et al.  Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis , 2018, Diabetes Therapy.

[11]  S. Halimi,et al.  Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild‐to‐moderate renal impairment , 2018, Diabetes, obesity & metabolism.

[12]  J. Rosenstock,et al.  More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial , 2018, Diabetes Care.

[13]  R. Roussel,et al.  A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study , 2018, Diabetes Care.

[14]  M. Matsuhisa,et al.  The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society , 2018, Diabetology International.

[15]  T. Bailey,et al.  Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin , 2018, Diabetes, obesity & metabolism.

[16]  M. Riddle,et al.  Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension). , 2017, Diabetes & metabolism.

[17]  R. Bergenstal,et al.  Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. , 2017, Diabetes & metabolism.

[18]  T. Heise,et al.  New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1 , 2014, Diabetes Care.

[19]  C. Cobelli,et al.  Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. , 2014, The Journal of clinical endocrinology and metabolism.

[20]  Alan Bernjak,et al.  Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk , 2014, Diabetes.

[21]  Amy L Clark,et al.  Even Silent Hypoglycemia Induces Cardiac Arrhythmias , 2014, Diabetes.

[22]  Jennifer Y. Liu,et al.  Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. , 2014, JAMA internal medicine.

[23]  P. Cryer,et al.  Mechanisms of hypoglycemia-associated autonomic failure in diabetes. , 2013, The New England journal of medicine.

[24]  K. Ohe,et al.  Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. , 2013, International heart journal.

[25]  J. Vora,et al.  Insulin Use in Elderly Adults: Risk of Hypoglycemia and Strategies for Care , 2012, Journal of the American Geriatrics Society.

[26]  Mark Woodward,et al.  Severe hypoglycemia and risks of vascular events and death. , 2010, The New England journal of medicine.

[27]  Y. Iwamoto,et al.  Comparison of the prevalence of chronic kidney disease in Japanese patients with Type 1 and Type 2 diabetes , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[28]  Michael E. Miller,et al.  The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study , 2010, BMJ : British Medical Journal.

[29]  A. Farmer,et al.  Three-year efficacy of complex insulin regimens in type 2 diabetes. , 2009, The New England journal of medicine.

[30]  M. Zhan,et al.  Frequency of hypoglycemia and its significance in chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[31]  Kristine Yaffe,et al.  Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. , 2009, JAMA.

[32]  Ronald J. Kallen,et al.  Hypoglycemia , 1980 .

[33]  No Authors.  Standards of Medical Care in Diabetes — 2021 , 2022, KIDNEYS.